Evidence map›Paper›PMID 41613546›Full record

ArticleFrontiers in oncology2025

Genetic investigation of a Tunisian family with Lynch syndrome: a case report.

Rania Abdelmaksoud-Dammak, Nihel Ammous-Boukhris, Souhir Guidara, Slim Charfi, Ameni Feki, Manel Guirat, Rahma Daoud, Hassen Kamoun, Tahya Sellami-Boudawara, Afef Khanfir and 1 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rania Abdelmaksoud-DammakCenter of Biotechnology of Sfax, Laboratory of Eukaryotes Molecular Biotechnology. University of Sfax, Sfax, Tunisia.
Nihel Ammous-BoukhrisCenter of Biotechnology of Sfax, Laboratory of Eukaryotes Molecular Biotechnology. University of Sfax, Sfax, Tunisia.
Souhir GuidaraDepartment of Human Genetics, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia.
Slim CharfiDepartment of Anatomo-pathology, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia.
Ameni FekiDepartment of Medical Oncology, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia.
Manel GuiratDepartment of Human Genetics, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia.
Rahma DaoudDepartment of Surgery, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia.
Hassen KamounDepartment of Human Genetics, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia.
Tahya Sellami-BoudawaraDepartment of Anatomo-pathology, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia.
Afef KhanfirDepartment of Medical Oncology, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia.
Raja Mokdad-GargouriCenter of Biotechnology of Sfax, Laboratory of Eukaryotes Molecular Biotechnology. University of Sfax, Sfax, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aimed to characterize the clinical and molecular features of a Tunisian family suspected of Lynch syndrome (LS) and identify the segregating pathogenic variant(s). Methods: A three-generation consanguineous family from the south of Tunisia with six members was recruited. Clinical diagnosis of LS was suspected according to the criteria of Amsterdam. A comprehensive molecular analysis was conducted, including immunohistochemical staining for mismatch repair (MMR) proteins, microsatellite instability (MSI) testing, targeted next-generation sequencing (NGS), and confirmatory Sanger sequencing. Iterative Threading ASSEmbly Refinement (I-TASSER) was used to analyze changes in the functional domains of mutant proteins. Results: Five members of the family developed cancer before the age of 45, including four cases of colorectal cancer and one case of glioblastoma. Immunohistochemical analysis of the proband showed complete loss of MSH2 and MSH6 protein expression, consistent with a high MSI (MSI-H) phenotype. Germline testing identified a pathogenic frameshift variant in MSH2 (NM_000251: c.687delA, p.Ala230LeuTer16) in the proband, her father, and two of her brothers, whereas her healthy sister did not carry the variant. An additional germline pathogenic variant in MUTYH (NM_001048171: c.1143_1144dupG, p.Glu382GlyTer43) was detected only in the proband's father and one of her brothers and was absent in the proband. Moreover, the proband later developed an extracolonic malignancy, a right ovarian tumor. NGS analysis of the tumor tissue revealed a pathogenic BRCA2 variant (c.1813delA, p.Ile605TyrTer9), which provides a potential target for personalized therapy. This case report highlights the co-segregation of a rare pathogenic MSH2 variant in a Tunisian family and underscores its clinical implications for improving the management and surveillance of patients with Lynch syndrome.

Indexed as

colorectal cancerLynch syndromeMMR genespathogenic varianttargeted-NGS

Identifiers

PMID41613546
PMCPMC12847019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.